The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results
Abstract
Purpose: We studied the safety, clinical activity, and pharmacokinetics (PK) of AG-013736, an oral receptor tyrosine kinase inhibitor of vascular endothelial cell growth factor, platelet-derived growth factor, and c-Kit, in patients with advanced cancer. Patients and Methods: Patients received fixed doses of AG-013736 orally in 28-day cycles. In the first cohort, patients initially received two single test doses of AG-013736 (10 and 30 mg); subsequent dosing was determined by individual PK parameters. Doses in subsequent cohorts were assigned by using a traditional dose-escalation/de-escalation rule based on observed toxicities in the current and previous cohorts. PK analysis included evaluation of the effect of food and antacid. Results: Thirty-six patients received AG-013736 at doses ranging from 5 to 30 mg by mouth twice daily. The dose-limiting toxicities observed included hypertension, hemoptysis, and stomatitis and were seen primarily at the higher dose levels. The observed hypertension was manageable with medication. Stomatitis was generally tolerable and managed by dose reduction or drug holidays. AG-013736 was absorbed rapidly, with peak plasma concentrations observed within 2 to 6 hours after dosing. The maximum-tolerated dose and recommended phase II dose of AG-013736 is 5 mg, twice daily, administered in the fasted state. No significant drug interaction with antacid was seen. There were three confirmed partial responses and other evidence of clinical activity. Conclusion: In this study, we have demonstrated clinical activity and safety of AG-013736 in patients with advanced solid tumors and identified the dose for phase II testing. The unique phase I study design allowed early identification of important absorption and metabolic issues critical to phase II testing of this agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Role of angiogenesis in tumor growth and metastasis
Folkman, J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.37263 · Cited by 2,404
Role of angiogenesis in tumor growth and metastasis
FOLKMAN, J. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70065-1 · Cited by 2,400
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Blood Vessel Formation: What Is Its Molecular Basis?
Folkman, J., & D'Amore, P. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81810-3 · Cited by 1,215
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189
Role of Akt Signaling in Vascular Homeostasis and Angiogenesis
Shiojima, I., & Walsh, K. (2002) · Circulation Research · doi:10.1161/01.res.0000022200.71892.9f · Cited by 1,012
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988
Hlatky, L. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.12.883 · Cited by 787
Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 757
Fundamental Concepts of the Angiogenic Process
Folkman, J. (2003) · Current Molecular Medicine · doi:10.2174/1566524033479465 · Cited by 666
Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.
Bellamy, W. T., Richter, L., Frutiger, Y. M., & Grogan, T. M. (1999) · PubMed · Cited by 515
Ciardiello, F., Bianco, R., Caputo, R., Caputo, R., Damiano, V., Troiani, T., Melisi, D., De Vita, F., De Placido, S., Bianco, A. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1100-03 · Cited by 347
O'Farrell, A.-M., Foran, J. M., Fiedler, W., Serve, H. L., Paquette, R. L., Cooper, M. A., Yuen, H. A., Louie, S. G., Kim, H., Nicholas, S., et al. (2003) · PubMed · Cited by 310
Fontanini, G., Vignati, S., Boldrini, L., Chinè, S., Silvestri, V., Lucchi, M., Mussi, A., Angeletti, C. A., & Bevilacqua, G. (1997) · PubMed · Cited by 306
Poon, R. T.-P., Ng, I. O.-L., Lau, C., Yu, W.-C., Yang, Z.-F., Fan, S.-T., & Wong, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.089 · Cited by 285
Bouloumié, A. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00228-4 · Cited by 281
Liu, G., Rugo, H. S., Wilding, G., McShane, T. M., Evelhoch, J. L., Ng, C., Jackson, E., Kelcz, F., Yeh, B. M., Lee, F. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.143 · Cited by 260
Self-citationAngiogenesis and prostate cancer: identification of a molecular progression switch.
Huss, W. J., Hanrahan, C. F., Barrios, R. J., Simons, J. W., & Greenberg, N. M. (2001) · PubMed · Cited by 253
Vascular Endothelial Cell Growth Factor (VEGF), An Emerging Target for Cancer Chemotherapy
Shinkaruk, S., Bayle, M., Lain, G., & Deleris, G. (2003) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011033353452 · Cited by 219
VEGF blocking therapy in the treatment of cancer
Glade-Bender, J., Kandel, J. J., & Yamashiro, D. J. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.2.263 · Cited by 171
Angiogenesis Inhibitors: A New Class of Drugs
Folkman, J. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.212 · Cited by 164
Senger, D. R. (1996) · Europe PMC (PubMed Central) · Cited by 155
Krøll, J., & Waltenberger, J. L. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1729 · Cited by 152
Stopeck, A., Sheldon, M., Vahedian, M., Cropp, G. F., Gosalia, R., & Hannah, A. L. (2002) · PubMed · Cited by 150
Regulatory considerations for preclinical development of anticancer drugs
DeGeorge, J. J., Ahn, C., Andrews, P. A., et al. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050726 · Cited by 124
Bevacizumab in the Treatment of Breast Cancer: Rationale and Current Data
Rugo, H. S. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-43 · Cited by 108
Self-citationTakahashi, R., Tanaka, S., Kitadai, Y., Sumii, M., Yoshihara, M., Haruma, K., & Chayama, K. (2003) · Oncology · doi:10.1159/000069316 · Cited by 105
Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584
THOMAS, A., Morgan, B., Drevs, J., Unger, C., Wiedenmann, B., Vanhoefer, U. J., Laurent, D., Dugan, M. H., & Steward, W. P. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70023-2 · Cited by 97
Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin.
Mundhenke, C., Thomas, J. P., Wilding, G., Lee, F. T., Kelzc, F., Chappell, R. J., Neider, R. S., Sebree, L., & Friedl, A. (2001) · PubMed · Cited by 87
Self-citationScience, medicine, and the future: Antivascular therapy: a new approach to cancer treatment
Hayes, A. J., Li, L. Y., & Lippman, M. E. (1999) · BMJ · doi:10.1136/bmj.318.7187.853 · Cited by 61
Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors
Sun, L. (2000) · Drug Discovery Today · doi:10.1016/s1359-6446(00)01534-8 · Cited by 53
Molecular biological design of novel antineoplastic therapies
Vulfovich, M., & Saba, N. F. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.6.577 · Cited by 9
Cited by
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E., Kim, S., Bycott, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 623
Self-citationRixe, O., Bukowski, R. M., Michaelson, M. D., Wilding, G., Hudes, G. R., Bolte, O., Motzer, R. J., Bycott, P., Liau, K. F., Freddo, J., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70285-1 · Cited by 435
Self-citationPhase I Trial of Pazopanib in Patients with Advanced Cancer
Hurwitz, H. I., Dowlati, A., Saini, S., Savage, S., Suttle, A. B., Gibson, D. M., Hodge, J. P., Merkle, E. M., & Pandite, L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2740 · Cited by 418
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
KATOH, M. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2620 · Cited by 405
Metadata
- Authors
- Rugo, H. S., Herbst, R. S., Liu, G., Park, J. W., Kies, M. S., Steinfeldt, H. M., Pithavala, Y. K., Reich, S. D., Freddo, J. L., & Wilding, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-08-20
- Volume
- 23
- Issue
- 24
- Pages
- 5474-5483
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2096514095
- Cited by
- 486
- References
- 39
- FWCI
- 11.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.